Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Haematologica|February 14, 2007
Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experienceHendrik-Tobias Arkenau, Geoff Chong, David Cunningham, et al.
Annals of Hematology|February 17, 2016
Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern eraAzim Jalali, Francis J Ha, Geoff Chong, et al.
JCO Oncology Practice|June 26, 2020
Routine Blood Tests in Asymptomatic Patients With Indolent Lymphoma Have Limited Ability to Detect Clinically Significant Disease ProgressionOliver A Piercey, Zoe Loh, Joanna Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2011
Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferationDanny Rischin, David C Bibby, Geoff Chong, et al.
Current Rheumatology Reports|September 3, 2018
A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of MalignancyPeter K K Wong, Hanish Bagga, Claire Barrett, et al.
Neuro-Oncology Advances|June 27, 2025
Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRIJack O'Shaughnessy, Arina Martynchyk, Sze Ting Lee, et al.
Blood Advances|January 24, 2025
Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR studyAllison Barraclough, Sze Ting Lee, Melinda Burgess, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2012
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancerAndrew J Weickhardt, Tim J Price, Geoff Chong, et al.
BMC Public Health|August 26, 2025
Exploring the association between Cultural and Linguistic Diversity (CALD) on treatment and outcomes in pancreatic cancer: an analysis of PURPLE real-world registry data from an Australian populationEmma Sanderson, Belinda Lee, Nadia Ayres, et al.
The Oncologist|March 31, 2025
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2Cathy Eng, Arvind Dasari, Sara Lonardi, et al.
Pageof 3